Tailored lipopeptide surfactants as potentially effective drugs to treat SARS-CoV-2 infection

[1]  Megan Cully.  A tale of two antiviral targets — and the COVID-19 drugs that bind them , 2021, Nature Reviews Drug Discovery.

[2]  U. Das.  Bioactive lipid-based therapeutic approach to COVID-19 and other similar infections , 2021, Archives of medical science : AMS.

[3]  C. Day,et al.  Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions , 2021, mBio.

[4]  C. Alabi,et al.  Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets , 2021, Science.

[5]  M. Amin,et al.  Role of arachidonic cascade in COVID-19 infection: A review , 2021, Prostaglandins & Other Lipid Mediators.

[6]  O. Lequin,et al.  Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection , 2021, Communications Biology.

[7]  Yoshimasa Tanaka,et al.  Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines , 2021, Biomedicine & Pharmacotherapy.

[8]  L. Berrino,et al.  Therapeutic strategies to fight COVID‐19: Which is the status artis? , 2021, British journal of pharmacology.

[9]  Parth Sarthi Sen Gupta,et al.  ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2 , 2020, Journal of proteome research.

[10]  A. El-Kadi,et al.  Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles , 2020, Emergent Materials.

[11]  Yasser B. Ruiz-Blanco,et al.  Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers , 2020, Journal of the American Chemical Society.

[12]  U. S. Jijith,et al.  Surfactant-based prophylaxis and therapy against COVID-19: A possibility , 2020, Medical Hypotheses.

[13]  S. Mukherjee,et al.  In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.

[14]  Martin Stahl,et al.  Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 , 2020, Cell.

[15]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[16]  U. Das.  Can Bioactive Lipids Inactivate Coronavirus (COVID-19)? , 2020, Archives of Medical Research.

[17]  Y. Nagashima,et al.  Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models , 2019, The Journal of Biological Chemistry.

[18]  E. Koepf,et al.  Evaluation of eco‐friendly zwitterionic detergents for enveloped virus inactivation , 2017, Biotechnology and bioengineering.

[19]  J. Pérez-Gil,et al.  Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy. , 2014, Biochimica et biophysica acta.

[20]  T. Brock.  Capturing Proteins that Bind Polyunsaturated Fatty Acids: Demonstration Using Arachidonic Acid and Eicosanoids , 2008, Lipids.

[21]  H. Onyuksel,et al.  Mechanistic Studies on Surfactant-Induced Membrane Permeability Enhancement , 2000, Pharmaceutical Research.

[22]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[23]  P. Janssen.  How to Design the Ideal Drug of the Future , 1999 .